[1] CHANKONG T, THEERA UMPON N, AUEPHANWIRIYAKUL S. Automatic cervical cell segmentation and classification in Pap smears[J]. Comput Meth Prog Bio, 2014, 113(2):539-556.
[2] O′KEEFFE E, CAMPBELL M. Modulating the paracellular pathway at the blood-brain barrier:current and future approaches for drug delivery to the CNS[J]. Drug Discov Today Technol, 2016, 20:35-39.
[3] JAFARI B, POURSEIF M M, BARAR J, et al. Peptide-mediated drug delivery across theblood-brain barrierfor targeting brain tumors[J]. Expert Opin Drug Deliv, 2019, 16(6):583-605.
[4] CHEN K T, WEI K C, LIU H L.Theranostic strategy of focused ultrasound induced blood-brain barrier opening for CNS disease treatment[J]. Front Pharmacol, 2019, 10:86.
[5] VAN TELLINGEN O, YETKIN-ARIK B, DE GOOIJER M C, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment[J]. Drug Resistance Updat, 2015, 19:1-12.
[6] HENDRIEKS B K, COHEN-GADOL A A, MILLER J C. Novel delivery methods bypassing the blood-brain and blood-tumor barriers[J]. Neurosurg Focus, 2015, 38(3):1-15.
[7] ASHFAQ U A, RIAZ M, YASMEEN E, et al. Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment[J]. Critl Rev Ther Drug Carrier Syst, 2017, 34(4):317-358.
[8] BUSSARD K M, MUTKUS L, STUMPF K, et al. Tumor-associated stromal cells as key contributors to the tumor microenvironment[J]. Breast Cancer Res, 2016, 18(1):84.
[9] XU C, LIU K.Joint effects of bradykin in and papaverine on blood-tumor barrier permeability in brain of rats[J]. Chin J Public Health(中国公共卫生), 2018, 34(8):1117-1119.
[10] LIU L B, LIU X B, MA J.Bradykinin increased the permeability of BTB via NOS/NO/ZONAB-mediating down-regulation of claudin-5 and occludin[J]. Bioche Bioph Res Commun, 2015, 464(1):118-125.
[11] ZHANG H, GU Y T, XUE Y X. Bradykinin-induced blood brain tumor barrier permeability increase is mediated by adenosine 5′-triphosphate-sensitive potassium channe [J]. Brain Res, 2007, 1144:33-41.
[12] LIU L B, XUE Y X, LIU Y H, et al. Bradykinin increases blood-tumor barrier permeability by down-regulating the expression levels of ZO-1, occludin, and claudin-5 and rearranging actin cytoskeleton[J]. J Neuro Sci Res, 2010, 86(5):1153-1168.
[13] SU B, WANG R, XIE Z, et al. Effect of retro-inverso isomer of bradykinin on size-dependent penetration of blood-brain tumor barrier[J]. Small, 2018, 14(7):1702331-1702340.
[14] XIE Z, SHEN Q, XIE C, et al. Retro-inverso bradykinin opens the door of blood-brain tumor barrier for nanocarriers in glioma treatment[J]. Cancer Lett, 2015, 369(1):144-151.
[15] KOICHIRO M, TAKANORI I, SHIN N, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7[J]. Neurosurgery, 1996, 39(1):125-134.
[16] NAKANO S, MATSUKADO K, BLACK K. Enchanced cytokines delivery and intercellular adhesion molecule 1 (lCAM-1) expression in glioma by intracarotid infusion of bradykinin analog, RMP-7[J]. Neurol Res, 1997, 19(5):501-508.
[17] PRADOS M D, SCHOLD S C, FINE H A, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 incombination with carboplatin administered intravenously for the treatment ofrecurrent malignant glioma[J]. Neuro-Oncology, 2003, 5(2):96-103.
[18] LIU X, CHANG Y, REINHART P H, et al. Cloning and characterization of glioma BK, a novel BK channel isoform highly expressed in human glioma cells[J]. J Neurosci, 2002, 22(5):1840-1849.
[19] NINGARAJ N S, SANKPAL U T, KHAITAN D, et al. Modulation of K_Ca channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model[J]. Cancer Biol Ther, 2009, 8(20):1924-1933.
[20] HU J, YUAN X, KOM H K, et al. Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model[J]. Mol Cancer, 2007, 6(1):22-22.
[21] NINGARAJ N S, RAO M, HASHIZUME K, et al. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels[J]. J Pharmacol Exp Ther, 2002, 301(3):838-851.
[22] CAI R P, XUE Y X, HUANG J, et al. NS1619 Regulates the expression of caveolin-1 protein in a time-dependent manner via ROS/PI3K/PKB/FoxO1 signaling pathway in brain tumor microvascular endothelial cells[J]. J Neur Sci, 2016, 369:109-118.
[23] EMILY B. Ion channels in development and cancer[J]. Annual Rev Cell Develop Bio, 2015, 31(1):231-247.
[24] DIVYA K, NINGARAJ N S. Targeting potassium channels for increasing delivery of imaging agents and therapeutics to brain tumors[J]. Front Pharmacol, 2013, 4(4):62.
[25] NINGARAJ N S, SANKPAL U T, KHAITAN D, et al. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival[J]. Eur J Pharmacol, 2009, 602(2-3):188-193.
[26] GU Y T, XUE Y X, WANG Y F, et al. Minoxidil sulfate induced the increase in blood-brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway[J]. Neuropharmacology, 2013, 75:407-415.
[27] HOU L, FENG H, ZHANG P. Expressions and clinical significance of P glycoprotein and multidrug resistance associated protein inbrain glioma [J]. Chin J Clin Oncol Rehabil(中国肿瘤临床与康复), 2018, 25(4):390-393.
[28] DEMEULE M, SHEDID D, EDITH BEAULIEU, et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors[J]. Int J Cancer, 2001, 93(1):62-66.
[29] MU Z J. Effect of quercetin on expression of p-glycoprotein in blood-brain barrier in glioma rats[J]. Strait Pharm J(海峡药学), 2015, 27(2):25-26.
[30] YANG M, CAI S Z, WEI J, et al.Inhibitory effect of endostatin on the expression of phosphoglucoprotein in multidrug resistance glioma cell line GL15 cells anditsmeanings[J]. Chin J Clin Neurosurg(中国临床神经外科杂志), 2012, 17(2):97-99.
[31] CARAGLIN M, ADDEO R, COSTANZO R, et al. Phase II study of temozolomide plus pegylatedliposomal doxorubicin in the treatment of brain metastases from solid tumours[J]. Cancer Chemother Pharmacol, 2006, 57(1):34-39.
[32] ZHANG R, SAITO R, SHIBAHARA I, et al. Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells[J]. J Neuro Oncol, 2016, 126(2):235-242.
[33] CHUA C, ZAIDEN N, CHONG K H, et al. Characterization of a side population of astrocytoma cells in response to temozolomide[J]. Neurosurg, 2008, 109:856-866.
[34] BLEAU A M, HAMBARDZUMYAN D, OZAWA T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells[J]. Cell Stem Cell, 2009,4:226-235.
[35] JIN Y, BIN Z Q, QIANG H, et al. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma[J]. Cancer Res Clin Oncol, 2009, 135:1369-1376.
[36] BHATIA P, BERNIER M, SANGHVI M, et al. Breast cancer resistant protein (BCRP/ABCG2) localizes to the nucleus in glioblastoma multiforme cells[J]. Xenobiotica, 2012, 42(8):748-755.
[37] WANG N B, ZHANG Q X, NING B L, et al. β-Asarone promotes temozolomide′s entry into glioma cells and decreases the expression of P-glycoprotein and MDR1[J]. Biomed Pharmacother, 2017, 90:368-374.
[38] WANG N B, ZHANG Q X, NING B L, et al. Comparison research on four effective constituent of resuscitation-inducing aromatic herbs in promoting temozolomide into U251 cells and the mechanism in decreasing drug resistance[J]. China J Tradit Chin Med Pharm(中华中医药杂志), 2017, 32(5):2206-2209.
[39] DUAN M M, XING Y M, GUO J Q, et al. Borneol increases blood-tumour barrier permeability by regulating the expression levels of tight junction-associated proteins[J]. Pharm Biol, 2016, 54(12):3009-3018.
[40] XING Y M. Role of MAPKss Signal Transduction Pathway in Natural Borneol Mediated Blood Tumor Barrier Permeability Increase[D]. Guangzhou University Chin Med(广州中医药大学),2016.
[41] LIU W J, YIN Y B, SUN J Y, et al. Natural borneol is a novel chemosensitizer that enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage[J]. Oncol Targets Ther, 2018, 11:5429-5439.
[42] GUO Y Y, WANG P Y.Chemo-sensitization effect of borneol combined with paclitaxel on brain glioma cell lines[J]. Asia-Pacific Tradit Med(亚太传统医药), 2018, 14(9):9-11.
[43] SU J, LAI H, CHEN J, et al. Natural borneol, a monoterpenoid compound, potentiates selenocystine-induced apoptosis in human hepatocellular carcinoma cells by enhancement of cellular uptake and activation of ROS-mediated DNA damage[J]. PLoS One, 2013, 8(5).
[44] WU T, ZHANG A Q, ZHOU Q Q, et al. Relationship between extent of borneol open blood-brain tumor barrier and H₂ receptor expression[J]. J Tradit Chin Med(中国中医药学刊), 2016, 34(5):1081-1083.
[45] MOHAMMAD A S, GRIFFITH J I, AKINS C E, et al. Liposomal irinotecan accumulates in metastatic lesions, crosses the blood-tumor barrier (BTB), and prolongs survival in an experimental model of brain metastases of triple negative breast cancer[J]. Pharm Res, 2018, 35(2):31.
[46] XU Y L, YING X, WANG Y H, et al. Research for inhibitory effect of resveratrol liposomes on C6 glioma cells[J]. Chin J Exp Tradit Med Form(中国实验方剂学杂志), 2017, 23(18):1-6.
[47] ZHAO Y, REN W, ZHONG T, et al. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity[J]. J Controlled Release, 2016, 222:56-66.
[48] HAN W, YIN G, PU X, et al. Glioma targeted delivery strategy of doxorubicin-loaded liposomes by dual-ligand modification[J]. J Biomater Sci Polym Ed, 2017, 28(15):1695-1712.
[49] BELHADJ Z, ZHAN C, YING M, et al. Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment[J]. Oncotarget, 2017, 8(40):66889-66900.
[50] YING M, ZHAN C, WANG S, et al. Liposome-based systemic glioma-targeted drug delivery enabled by All-D peptides[J]. ACS Appl Mater Interfaces, 2016, 8:29977-29985.
[51] LIN X X, LI J X, GUO X Y. Research of interleukin-13 modified BCNU micelles in targeted therapy for glioma[J]. Pharm Clin Res(药学与临床研究), 2016, 24(4):273-277.
[52] PANJA S, DEY G, BHARTI R, et al. Tailor-made temperature-sensitive micelle for targeted and on-demand release of anticancer drugs[J]. ACS Appl Mater Interfaces, 2016, 8(19):12063-12074.
[53] YUAN P, HANG J S, XIAO H, et al. Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment[J]. Inter J Nanomed, 2018, 13:3467-3480.
[54] JIAO X X, HU C L, HE M, et al. Preparation and in vitro evaluation of angiopep-2-modified brain-targeting polypeptide micelles[J]. Acad J Second Mil Med Univ(第二军医大学学报), 2018, 39(4):411-416.
[55] MAO J, RAN D, XIE C, et al. EGFR/EGFRvIII Dual-targeting peptide-mediated drug delivery for enhanced glioma therapy[J]. ACS Appl Mater Interfaces, 2017, 9(29):24462-24475.
[56] REN Y, ZHAN C, GAO J, et al. A D-peptide ligand of integrins for simultaneously targeting angiogenic blood vasculature and glioma cells[J]. Mol Pharm, 2018, 15(2):592-601.
[57] TIAN Y, MI G J, CHEN Q, et al. Acid-induced activated cell-penetrating peptide-modified cholesterol-conjugated polyoxyethylene sorbitol oleate mixed micelles for pH-triggered drug release and efficient brain tumor targeting based on a charge reversal mechanism[J]. ACS Appl Mater Inter, 2018, 10:43411-43428.
[58] MIURA Y, TAKENAKA T, TOH K, et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier[J]. ACS Nano, 2013, 7(10):8583-8592.
[59] QUADER S, LIN X, CHEN Y, et al. cRGD Peptide-installed epirubicin-loaded polymeric micelles for effective targeted therapy against brain tumors[J]. J Controlled Release, 2017, 258:56-66.
[60] CHEN X S, TAI L Y, GAO J, et al. A stapled Peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation[J]. J Controlled Release, 2015, 218:29-35.
[61] RAN D, MAO J, ZHAN C, et al. D-retro-enantiomer of quorum sensing peptides-modified polymeric micelles for brain tumor targeted drug delivery[J]. ACS Appl Mater Inter, 2017, 9(31):25672-25682.
[62] KANG J H, CHO J, KO Y T. Investigation on the effect of nanoparticle size on the blood-brain tumour barrier permeability by in situ perfusion via internal carotid artery in mice[J]. J Drug Target, 2019, 27(1):103-110.
[63] XING H L.Study on glioma targeted drug delivery system via IL-13Ra2mediated endocytosis[C]. CPA: China Pharmaceutical Congress, 2014:9.
[64] JIANG Y, WANG X, LIU W, et al. Enhanced antigliomaefficacy of ultrahigh loading capacity paclitaxel prodrug conjugate self-assembled targeted nanoparticles[J]. ACS Appl Mater Inter, 2017, 9(1):211-217.
[65] WANG X, ZHANG Q, LV L, et al. Glioma and microenvironment dual targeted nanocarrier for improved antiglioblastoma efficacy[J]. Drug Deliv, 2017, 24(1):1401-1409.
[66] CUI L, WANG Y, LIANG M, et al. Dual-modified natural high density lipoprotein particles for systemic glioma-targeting drug delivery[J]. Drug Deliv, 2018, 25(1):1865-1876.
[67] ZHAI M F, WANG Y L, ZHANG L G, et al. Glioma targeting peptide modified apoferritin nanocagea[J]. Drug Deliv, 2018, 25(1):1013-1024.
[68] HU J, HU K, CHENG Y . Tailoring the dendrimer core for efficient gene delivery[J]. Acta Biomater, 2016, 35:1-11.
[69] XU L, ZHANG H, WU Y. Dendrimer advances for the central nervous system delivery of therapeutics[J]. ACS Chem Neurosci, 2014, 5(1):2-13.
[70] LIU P, HUANG Z, CHEN Z, et al. Silver nanoparticles: a novel radiation sensitizer for glioma?[J]. Nanoscale, 2013, 5(23):11829-11836.
[71] HUANG A H,HAN S P,LU Y P, et al. Preparation and in vitro evaluation of arsenic trioxide glioma targeting drug delivery system loaded by PAMAM dendrimers co-modified with RGDyC and PEG[J]. Chin J Chin Mater Med(中国中药杂志), 2018, 43(8):1618-1625.
[72] LIU Y P, HAN A P, ZHENG H Y, et al. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system [J]. Int J Nanomed, 2018, 13:5937-5952.
[73] SHARMA A K, GUPTA L, SAHU H, et al. Chitosan engineered PAMAM dendrimers as nanoconstructs for the enhanced anti-cancer potential and improved in vivo brain pharmacokinetics of temozolomide[J]. Pharm Res, 2018, 35(1):9.
[74] GAO S, LI J F, JIANG C, et al. Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoaminedendrimer[J]. Drug Des Dev Ther, 2016, 10:1-11.
[75] LI J J, GUO M M, HAN S P, et al. Preparation and in vitro evaluation of borneol and folic acid co-modified doxorubicin loaded PAMMAM drug delivery system[J]. Acta Pharm Sin(药学学报), 2015, 50(7):899-905.
[76] XU X L, LI J J, HAN S P, et al. A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration[J]. Eur J Pharm Sci, 2016, 88:178-190.
[77] QIU J R, KONG L D, CAO X Y, et al. Enhanced delivery of therapeutic sirna into glioblastoma cells using dendrimer-entrapped gold nanoparticles conjugated with β-cyclodextrin[J]. Nanomaterials, 2018, 8(3):131.
[78] ZAREBKOHANA, NAJAFIF, MOGHIMIH R, et al. SRL-Coated PAMAM dendrimer nano-carrier for targeted gene delivery to the glioma cells and competitive inhibition by lactoferrin[J]. Iran J Pharm Res, 2016, 15(4):629-640.
[79] JIANGY, LV L, SHI H, et al. PEGylated Polyamidoamine dendrimer conjugated with tumor homing peptide as a potential targeted delivery system for glioma[J]. Colloids Surf B: Biointerfaces, 2016, 147:242-249.
[80] HAN S P, ZHENG H, LU Y, et al. A novel synergetic targeting strategy for glioma therapy employing borneol combination with angiopep-2-modified, DOX-loaded PAMAM dendrimer[J]. J Drug Target, 2018, 26(1):86-94.
[81] XIE H, LU W C, DING X H, et al. Study of hyaluronic acid chitosanbased microemulsion on the permeability of blood tumor barrierin rat[J]. J Chin Pharm Univ(中国医科大学学报), 2014, 43(8):703-705, 709.
[82] LU W C, XIE H, DING X H, et al. Therapeutic effect of hyaluronic acid chitosan-based microemulsion and carboplatin on glioma in rats[J]. J Shenyang Med Coll(沈阳医学院学报), 2016, 18(3):149-150, 153.
[83] SHINDER L, DEVARAJAN P V. Docosahexaenoic acid-mediated, targeted and sustained brain delivery of curcumin microemulsion[J]. Drug Deliv, 2017, 24(1):152-161.
[84] CHEN X, YANG H B, HU Y Q, et al. Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel[J]. Pharm Clin Res(药学与临床研究), 2013, 21(1):9-12.
[85] LI N, YE Y J, YANG M, et al. Evaluation of brain-targeting of nasal baicalin-phospholipid complex in situ gel[J]. Chin Pharm J(中国药学杂志), 2011, 46(16):1254-1258.
[86] HE W, XIAO M, GUO X X.Pharmacokinetics and braintargeting ability of gastrodin nasal in situ gel in rats[J]. Chin Pharm(中国药师), 2017, 20(1):68-72.
[87] XU Y Y.Paclitaxel and temozolomide Co-delivered nano composite thermo-sensitive gel system for glioblastoma[D]. Shanghai: Shanghai Jiaotong University, 2015.
[88] TURABEEM H, JEONGY H, RAMALINGAM P. N, N, N-trimethyl chitosan embedded in situ Pluronic F127 hydrogel for the treatment of brain tumor[J]. Carbohydrate Polymers, 2019, 203:302-309.
[89] ARYAL M, ARVANITIS C D, ALEXANDERPM, et al. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system[J]. Adv Drug Deliv Rev, 2014, 72:94-109.
[90] MCDANNOLDN, ARVANITIS C D, VYKHODTSEVAN, et al. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques[J]. Cancer Res, 2012, 72:3652-3663.
[91] ARVANITIS C D, LIVINGSTONEM S, VYKHODTSEVAN, et al. Controlled ultrasound-induced blood-brain barrier disruption using passive acoustic emissions monitoring[J]. PLoS One, 2012, 7(9):e45783.
[92] PARK J, ARYAL M, VYKHODTSEVA N, et al. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption[J]. J Controlled Release, 2017, 250:77-85.
[93] SHEN Y Y, PI Z, YAN, et al. Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts[J]. Int J Nanomed, 2017, 12:5613-5629.
[94] ZHANG Z, XIA C Y, LIU Y H, et al. Low frequency ultrasound selected for evaluating permeation of blood-tumor barrier: experimental study in rats[J]. Chin J Ultr Me(中国超声医学杂志), 2008(7):580-583.
[95] SONG Y, ZHENG X J, XIE Y X.The effect of caveolin-1 on occludin expression in the selective opened bloodtumor barrier irradiated by low-frequency ultrasound[J]. Prog Anato Sci(解剖科学进展), 2017, 23(2):119-122.
[96] XIA C Y, CONG X F, LIU Y H. Possible mechanisms of the increase in the permeability of the bloodtumor barrier obtained by combiing low-frequency ultrasound irradiation with small-dose bradykinin in rat[J]. Prog Anato Sci(解剖科学进展), 2011, 17(3):294-299.
[97] XIA C Y, LIU Y H, WANG P, et al. Low-frequency ultrasound irradiation increases blood-tumor barrier permeability by transcellular pathway in a rat glioma model[J]. J Mol Neurosci, 2012, 48(1):281-290.
[98] ZHANG J L, LIU H, DU X S, et al. Increasing of blood-brain tumor barrier permeability through transcellular and paracellular pathways by microbubble-enhanced diagnostic ultrasound in a C6 glioma model[J]. Front Neurosci-Switz, 2017, 11:86.
[99] SHEN S Y, YU H, LIU X B, et al. PIWIL1/piRNA-DQ593109 regulates the permeability of the blood-tumor barrier via the MEG3/miR-330-5p/RUNX3 axis[J]. Mol Ther-Nucl Acids, 2018, 10(C):412-425.
[100] GUO J, CAI H, MA J, et al. Long non-coding RNA NEAT1 regulates permeability of the blood-tumor barrier via miR-181d-5p-mediated expression changes in ZO-1, occludin, and claudin-5[J]. BBA-Mol Basis Dis, 2017, 1863(9):2240-2254.
[101] KAO J, HOUCK K, FAN Y, et al. Characterization of a novel tumorderived cytokine. Endothelial-monocyte activating polypeptide II[J]. J Biol Chem, 1994, 269(40):25106-25119.
[102] ZHAO L, ZHANG Y. miR-342-3p affects hepatocellular carcinoma cell proliferation via regulating NF-κB pathway[J]. Biochem Biophys Res Commun, 2015, 457(3):370-377.
[103] CHEN L, XUE Y, ZHENG J, et al. MiR-429 regulated by endothelial monocyte activating polypeptide-Ⅱ(emap-Ⅱ) influences blood-tumor barrier permeability by inhibiting the expressions of ZO-1, occludin and claudin-5[J]. Front Mol Neurosci, 2018, 11:35.
[104] XU X, LIU X B, XIE Y X, et al. Endothelial-monocyte-activating polypeptide Ⅱ increases blood-tumor barrier permeability by up-regulating LINC00263[J]. Prog Anato Sci(解剖科学进展), 2018, 24(1):41-44+48.
[105] JIAHUI L, LIBO L, SHUO C, et al. The role of miR-330-3p/PKC-α signaling pathway in low-dose endothelial-monocyte activating polypeptide-Ⅱ increasing the permeability of blood-tumor barrier[J]. Front Cell Neurosci, 2017, 11:358.
[106] GU Y T, CA R P, ZHANG C, et al. miR-132-3p boosts caveolae-mediated transcellular transport in glioma endothelial cells by targeting PTEN/PI3K/PKB/Src/Cav-1 signaling pathway[J]. Faseb J, 2019, 33(1):441-454.